Cancer patients with vein clots get a closer look: new study aims to fill treatment gap
NCT ID NCT07210671
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 40 times
Summary
This study looks at cancer patients who have a type of blood clot called superficial venous thrombosis (SVT). About 15-20% of SVTs happen in people with cancer, but there are no clear treatment guidelines for them. Researchers will observe 1,576 patients to see how different blood thinners affect the risk of clots coming back or getting worse. The goal is to gather real-world data to help doctors make better treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens
RECRUITINGAmiens, 80480, France
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.